FDA approves Pomalyst for advanced multiple myeloma

Author(s):

On Feb. 8, 2013, the U.S. Food and Drug Administration (FDA) approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease has progressed after being treated with other cancer drugs. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here